Altasciences Initiates Phase I Study in Healthy Normal Subjects for ST-2427, a Non-Opioid Analgesic for Acute Pain
13.5.2021 19:31:00 EEST | Business Wire | Press release
Altasciences is pleased to support SiteOne Therapeutics with a Phase I, randomized, double-blind, placebo-controlled study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. ST-2427 is a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain; by selectively targeting NaV1.7, ST-2427 aims to stop the electrical signals responsible for pain before they reach the central nervous system.
Amy Denvir, General Manager of Altasciences’ Kansas City clinical site, says, “We are proud to partner with SiteOne Therapeutics and help move this important therapeutic into clinical trials. Helping bring to market a new approach that may provide a non-opioid option to treat moderate- to-severe pain is an exciting prospect, and we look forward to delivering this ground-breaking research.”
Click here to read the SiteOne press release.
Altasciences has designed and conducted hundreds of first-in-human trials by offering comprehensive, full service, early development solutions. With a focus on developing sound strategies combined with operational efficiencies, the company minimizes the time taken to make critical go/no-go decisions by harmonizing clinical pharmacology services, biomarker capabilities, PK/PD analysis expertise, and program knowledge.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005827/en/
Contact information
Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xceedance Named a Leader and Star Performer in Everest Group’s Insurance Intermediaries Operations PEAK Matrix ® Assessment 202620.10.2026 17:00:00 EEST | Press release
Xceedance today announced it has been named a Leader and Star Performer in the Everest Group Insurance Intermediaries Operations PEAK Matrix® Assessment 2026. The assessment evaluated 18 providers based on market impact and their vision and capability to deliver insurance intermediary operations services. Everest Group identified Xceedance’s support for MGAs and MGUs across entity setup and licensing, underwriting, policy administration, finance, analytics, and claims as a key strength. The report also highlighted enabling rapid program launches and scaling through a licensed MGA shell, configurable workflows, and integrated operations. “Xceedance brings deep insurance expertise and a growing breadth of capabilities to support MGAs, brokers, and Lloyd’s market participants,” said Dinesh Udawat, Practice Director, Everest Group. “Its strategic acquisitions have expanded its agent and broker capabilities, while continued investments in AI and insurance-specific technology are enabling mo
92% of Compliance Leaders Want External Certification on AI Agents. None Exists for On-Chain Risk. Elliptic Just Built It, for Free.20.10.2026 17:00:00 EEST | Press release
Elliptic, the leader in on-chain risk management, today launched the first certification in governing AI agents for on-chain risk and financial crime compliance from the Elliptic Institute. The Certified Agentic On-Chain Risk Practitioner (CAORP) Foundation Level is free and open to anyone in the industry. The certification follows new Elliptic research in which 92% of senior risk, compliance and financial crime professionals said they would consider sending staff for external certification in agentic AI risk governance. The global research1 found a wide gap between that appetite and teams' current capability. Only 16% of respondents said they were very confident their team has the skills to govern an AI agent today, while 38% said they were not confident at all or had no capability yet. Nearly a third (31%) expect to send staff for certification within the next 12 months. The demand for training has arrived well ahead of anywhere to get it. The timing isn't optional. The EU AI Act now
Andersen Consulting Adds Collaborating Firm in Uzbekistan20.10.2026 16:30:00 EEST | Press release
Andersen Consulting expands its cybersecurity and business transformation capabilities through a Collaboration Agreement with Algoruni, a consulting firm based in Uzbekistan. Algoruni advises organizations on building cyber resilience, while addressing broader management, regulatory, and sustainability priorities. Operating out of Tashkent, the firm’s services span cybersecurity strategy and data protection, corporate governance and operational improvement, and ESG strategy and reporting, with an emphasis on practical solutions tailored to each client’s circumstances. “Every organization faces a different combination of risks and opportunities, which is why we believe effective solutions must start with the realities of the business,” said Alisher Zaynutdinov, managing director of Algoruni. “Becoming a collaborating firm of Andersen Consulting allows us to pair this approach with broader international resources and perspectives, giving us new ways to help clients turn complex challenge
International AI Strategist and Author Katie King to Keynote IAMPHENOM Europe 202620.10.2026 16:30:00 EEST | Press release
Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. Phenom also unveiled the conference agenda, which centres on the decisions European HR leaders face right now: turning AI, agents and automation into business outcomes, deploying tech with a compliant-first approach, and redesigning roles and skills for the future workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020028392/en/ Phenom announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. Phenom also unveiled the conference agenda, which centres on the
Inaugural Future Health Impact Challenge Documentary Released as Expressions of Interest Open for Second Challenge20.10.2026 16:26:00 EEST | Press release
Future Health – A Global Initiative by Abu Dhabi today premiered a documentary film about the inaugural Future Health Impact Challenge during the first day of the Abu Dhabi Future Health Summit. The film’s global launch, alongside the announcement of the second Challenge connects the Challenge’s initial results with its next phase with Expressions of Interest now open for the second edition. Delivered in collaboration with MIT Solve, the inaugural Impact Challenge demonstrates the transformative power of innovative solutions that accelerate the shift from reactive to anticipatory healthcare systems. With scenes filmed in Kigali, Medellín, São Paulo, Boston, and Abu Dhabi, the film shares personal commentary from the founders, local perspectives of the solutions in action, and insight from Future Health and MIT Solve. It follows the winner and two distinguished finalists as they turn signals from frontline consultations, mosquito surveillance, and routine blood tests into information th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom